TGTX

TGTX

USD

TG Therapeutics Inc. Common Stock

$33.845+0.775 (2.344%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$33.070

高値

$34.325

安値

$32.772

出来高

1.47M

企業ファンダメンタルズ

時価総額

5.4B

業種

バイオテクノロジー

United States

取引統計

平均出来高

2.11M

取引所

NCM

通貨

USD

52週レンジ

安値 $23.6現在値 $33.845高値 $46.48

関連ニュース

Analyst Upgrades

JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49

JP Morgan analyst Eric Joseph maintains TG Therapeutics with a Overweight and raises the price target from $46 to $49.

もっと見る
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49
GlobeNewswire

TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target

もっと見る
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
GlobeNewswire

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of

もっと見る
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
GlobeNewswire

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and

もっと見る
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。